Marie Terroir-Cassou-Mounat

Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

J. Bourhis, S. Broutin, A. Paci, 2015 .

Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer

E. Baudin, D. Hartl, S. Leboulleux, 2020, Cancers.

Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.

C. Robert, J. Rossignol, V. Ribrag, 2019, Immunotherapy.

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

S. Broutin, J. Delahousse, A. Paci, 2018, Leukemia.

Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.

T. de Baère, K. Boudjema, E. Assenat, 2020, The lancet. Gastroenterology & hepatology.

MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956)

M. Schlumberger, S. Bardet, A. Schiazza, 2021, Journal of the Endocrine Society.